REGNRegeneron Pharmaceuticals
Price
+25%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, no red flags, price roughly fair, growth steady, the market undecided.
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
In the company’s own words · 10-K filed Feb 4, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Regeneron Pharmaceuticals (REGN) reported revenue of $4.29B in Q2 2026 (quarter ended Jun 30, 2026), up 17% from the same quarter a year earlier. That came with net income of $1.30B (30% of revenue). For the full year FY2025, revenue was $14.3B (+1.0% year on year) and net income $4.50B. Its largest product in Q2 2026 was Share Of Profit Losses at $2.03B, 50% of the disclosed total, well ahead of EYLEAHD at 15%. The next results filing is expected around Jan 11, 2027, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 6, 2026On October 1, 2026, Regeneron Pharmaceuticals, Inc., a New York corporation (“Regeneron” or the “Company”), Sanofi Biotechnology SAS, a société par actions simplifée organized under the laws of France (“Sanofi Biotechnology”), and Sanofi, a société anonyme organized under the laws of France (“Sanofi Parent” and, with …Material agreement entered · Form 8-K
- Sep 30, 2026New Equity Awards for CEO and CSO Effective September 24, 2026 (the “Grant Date”), the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) granted, upon the approval of the independent, non-employee members of …Director or officer change · Form 8-K
- Jul 30, 2026Regeneron Reports Second Quarter 2026 Financial and Operating Results.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $4.05BThe company’s own SEC segment disclosure.
- Share Of Profit Losses$2.03B50%
- EYLEAHD$596.3M15%
- Eylea Net Product Sales$412.2M10%
- LIBTAYO Net Product Sales$342.6M8%
- Product And Service Other$193.3M5%
- Reimbursement Of Commercialization Related Expenses$188.8M5%
- Other (4)$286.2M7%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Biotechnology
The closest names by size in the same industry